Update on the treatment of chronic hepatitis C in HIV-infected patients

AIDS Reviews

Volumn 9, Issue 2, 2007, Pages 99-113

  Soriano, Vincent ^a   Barreiro, Pablo ^a   Martin Carbonero, Luz ^a   Vispo, Eugenia ^a   Garcia Samaniego, Javier ^a   Labarga, Pablo ^a   Gonzalez Lahoz, Juan ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Hepatitis C; HIV; Liver; Pegylated interferon; Ribavirin

Indexed keywords

ABACAVIR; ADOFEN; ANTIRETROVIRUS AGENT; ATAZANAVIR; CASBOL; CITALOPRAM; DIDANOSINE; DOBUPAL; DULOXETINE; EMTRICITABINE; ESCITALOPRAM; ESERTIA; FLUOXETINE; IRENOR; LAMIVUDINE; METHADONE; MIRTAZAPINE; NORFENAZIN; NORTRIPTYLINE; PARATONIN; PAROXETINE; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PRISDAL; PROTEINASE INHIBITOR; REBOXETINE; RECOMBINANT ERYTHROPOIETIN; RENEURON; REXER; RIBAVIRIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; VANDRAL; VASTAT; VENLAFAXINE; ZIDOVUDINE;

ALCOHOLISM; ANEMIA; ANTIVIRAL ACTIVITY; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; DEPRESSION; DOSE RESPONSE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG COMPETITION; DRUG CONTRAINDICATION; DRUG DEPENDENCE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENOTYPE; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERCHOLESTEROLEMIA; INSOMNIA; LIPOATROPHY; LIVER FAILURE; LIVER FIBROSIS; LOW DRUG DOSE; MENTAL DISEASE; OPTIMAL DRUG DOSE; PATIENT COMPLIANCE; PATIENT SELECTION; PREDICTION; PROGNOSIS; REVIEW; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTIVIRAL AGENTS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; POLYETHYLENE GLYCOLS; RIBAVIRIN;

EID: 34547526420     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (125)

1. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in HIV and HCV coinfected patients. Hepatology 1999;30:1054-8.
2. Martinez-Sierra C, Arizcorreta A, Diaz F, et al. Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with HCV and HIV. Clin Infect Dis 2003;36:491-8.
3. Martin-Cabonero L, Benhamou Y, Puoti M, et al. Incidence and predictors of severe liver fibrosis in HIV infected patients with chronic hepatitis C - a European collaborative study. Clin Infect Dis 2004;38:128-33.
4. Sulkowski M, Thomas D, Chaisson R, Moore R. Hepatotoxicity associated with antiretroviral therapy in adults infected with HIV and the role of hepatitis C or B virus infection. JAMA 2000;283:74-80.
5. Núñez M, Lana R, Mendoza J, Martín-Carbonero L, Soriano V. Risk factors for severe hepatic injury following the introduction of HAART. J Acquir Immun Defic Syndr 2001;27:426-31.
6. Perez-Olmeda M, Nuñez M, Romero M, et al. PEG-IFNα-2b + ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS 2003;17:1023-8.
7. Ballesteros A, Franco S, Fuster D, et al. Early HCV dynamics on PEG-IFN and ribavirin in HIV/HCV coinfection: indications for the investigation of new treatment approaches. AIDS 2004; 18:59-66.
8. Moreno L, Quereda C, Moreno A, et al. PEG-IFNα-2b + ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. AIDS 2004;18:67-73.
9. Chung R, Andersen J, Volberding P, et al. PEG-IFNα-2a plus ribavirin versus IFNα-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004;351:451-9.
10. Carrat F, Bani-Sadr F, Pol S, et al. PEG-IFNα-2b vs. standard IFNα-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients. JAMA 2004;292:2839-48.
11. Torriani F, Rodriguez-Torres M, Rockstroh J, et al. PEG-IFNα-2a plus ribavirin for chronic HCV infection in HIV-infected patients. N Engl J Med 2004;351:438-50.
12. Laguno M, Morillas J, Blanco JL, et al. PEG-IFNα-2b plus ribavirin compared with IFNα-2b plus ribavirin for treatment of HIV/ HCV-coinfected patients. AIDS 2004;18:F27-36.
13. Santin M, Shaw E, Garcia MJ, et al. Efficacy and safety of PEG-IFNα-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. AIDS Res Hum Retroviruses 2006;22: 315-20.
14. Voigt E, Schulz C, Klausen G, et al. PEG-IFNα-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-coinfected patients. J Infect 2006;53:36-42.
15. Soriano V, Pérez-Olmeda M, Rios P, Núñez M, García-Samaniego J, González-Lahoz J. HCV relapses after anti-HCV therapy are more frequent in HIV-infected patients. AIDS Res Hum Retroviruses 2004;20:351-4.
16. Sherman K, Shire N, Rouster S, et al. Viral kinetics in hepatitis C or hepatitis C/HIV-infected patients. Gastroenterology 2005;128: 313-27.
17. Soriano V, Puoti M, Sulkowski M, et al. Care of patients with hepatitis C and HIV coinfection. Updated recommendations from the HIV-HCV International Panel. AIDS 2004;18:1-12.
18. Alberti A, Clumeck N, Collins S, et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis Band C in HIV-coinfected patients. J Hepatol 2005;42: 615-24.
19. Cargnel A, Angeli E, Mainini A, et al. Open, randomized, multicentre Italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART. Antivir Ther 2005;10:309-17.
20. Manns M, McHutchison J, Gordon S, et al. PEG-IFNα-2b plus ribavirin compared with IFNα-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001;358:958-65.
21. Fried M, Shiffman M, Reddy R, et al. PEG-IFNα-2a plus ribavirin for chronic HCV infection. N Engl J Med 2002;347:975-82.
22. Cadranel J, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. Hepatology 2000;32: 477-81.
23. Bedossa P, Dalgere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003;38:1449-57.
24. Regev A, Berho M, Jeffers L, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002;97:2614-8.
25. Wong J, Koff R. Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. A cost-effectiveness analysis. Ann Intern Med 2000;133: 665-75.
26. Saito H, Tada S, Nakamoto N, et al. Efficacy of noninvasive elastometry on staging of hepatic fibrosis. Hepatol Res 2004;29: 97-103.
27. Ziol M, Handra-Luca A, Kettaneh A, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005;4:48-54.
28. Castera L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, FibroTest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005;128:343-50.
29. Colletta C, Smirne C, Fabris C, et al. Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases. Hepatology 2005;42:838-45.
30. Myers R, Benhamou Y, Imbert-Bismut F, et al. Serum biochemical markers accurately predict liver fibrosis in HIV and HCV coinfected patients. AIDS 2003;17:721-5.
31. Forns X, Ampurdanes S, Llovet J, et al. Identification of chronic: hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002;36:986-92.
32. Patel K, Gordon S, Jacobson I, et al. Evaluation of a panel of noninvasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. J Hepatol 2004;41:935-42.
33. Kelleher T, Mehta S, Bhaskar R, et al. Prediction of hepatic fibrosis in HIV/HCV coinfected patients using serum fibrosis markers: the SHASTA index. J Hepatol 2005;43:78-84.
34. Sterling R, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/ HCV coinfection. Hepatology 2006;43:1317-25.
35. Parkes J, Guha I, Roderick P, Rosenberg W. Performance of serum marker panels for liver fibrosis in chronic hepatitis C. J Hepatol 2006;44:462-74.
36. Macias J, Giron-Gonzalez JA, Gonzalez-Serrano M, et al. Prediction of liver fibrosis in HIV/HCV-coinfected patients by simple noninvasive indexes. Gut 2006;55:409-14.
37. Nunes D, Fleming C, Offner G, et al. HIV infection does not affect the performance of noninvasive markers of fibrosis for the diagnosis of HCV-related liver disease. J Acquir Immune Defic Syndr 2005;40:538-44.
38. De Ledinghen V, Douvin C, Kettaneh A, et al. Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/HCV-coinfected patients. J Acquir Immune Defic Syndr 2006;41:175-9.
39. Andriulli A, Persico M, Iacobellis A, et al. Treatment of patients with HCV infection with or without liver biopsy. J Viral Hepat 2004;11:5,36-42.
40. Soriano V, Martin-Carbonero L, García-Samaniego J. Treatment of chronic HCV infection: we must target the virus or liver fibrosis? AIDS 2003;17:751-3.
41. Barreiro P, Martin-Carbonero L, Nuñez M, et al. Predictors of liver fibrosis in HIV-infected patients with chronic hepatitis C: assessment using transient elastometry and role of HCV genotype 3. Clin Infect Dis 2006;42:1032-9.
42. Foucher J, Chanteloup E, Vergniol J, et al. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 2006;55:310-2.
43. Berreiro P, Simarro N, Nuñez M, et al. Sustained virologic response following HCV therapy is associated with regression of liver fibrosis in HCV/HIV-coinfected patients. 13th CROI, Denver, Colorado, February 5-8 2006 [abstract 859].
44. Grando-Lemaire V, de Ledinghen V, Bourcier V, Ganne-Carrie N, Trinchet J, Beaugrand M. Liver stiffness measurement as a tool to measure liver fibrosis in treated patients with chronic hepatitis C. J Hepatol 2006;44(Suppl 2):214.
45. De Ledhingen V, Castera L, Foucher J, et al. Evaluation of fibrosis regression using FibroScan in HCV responder patients - a prospective controlled study. J Hepatol 2006;44(Suppl 2):210.
46. Aranzabal L, Casado JL, Moya J, et al. Influence of liver fibrosis on HAART-associated hepatotoxicity in patients with HIV and HCV coinfection. Clin Infect Dis 2005;40:588-93.
47. Regev A, Berho M, Jeffers L, et al. Sampling error and intra-observer variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002;97:2614-8.
48. Soriano V, García-Samaniego J, Bravo R, et al. IFNα for the treatment of chronic hepatitis C in patients infected with HIV. Clin Infect Dis 1996;23:585-91.
49. Mauss S, Klinker H, Ulmer A, et al. Response to treatment of chronic hepatitis C with IFNα in patients infected with HIV-1 is associated with higher CD4+ cell count. Infection 1998;26:16-9.
50. Dieterich D, Opravil M, Sasadeusz J, et al. Effect of baseline CD4+ % on the efficacy of PEG-IFNα-2a plus ribavirin - findings from the APRICOT. 46th ICAAC, San Francisco, September 2006 [abstract H-1888].
51. Hammer S, Saag M, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA Panel. JAMA 2006;296:827-43.
52. Gao B, Hong F, Radaeva S. Host factors and failure of IFN treatment in HCV. Hepatology 2004;39:880-90.
53. Zeuzem S. Heterogeneous virologic response rates to IFN-based therapy in patients with chronic hepatitis C: who responds less well? Ann Intern Med 2004;140:370-81.
54. Vento S, Di Perri G, Cruciani M, Garofano T, Concia E, Bassetti D. Rapid decline of CD4+ cells after IFN treatment in HIV-1 infection. Lancet 1993;341:958-9.
55. Pesce A, Taillan B, Rosenthal E. Opportunistic infections and CD4 lymphocytopenia with IFN treatment in HIV-1-infected patients. Lancet 1993;341:1597.
56. Labarga P, Soriano V, Martin-Carbonero L, et al. Liver tolerance of antiretrovirals is improved in HIV-infected patients with chronic hepatitis C that attain HCV clearance after IFN-based therapy. J Infect Dis 2007 [in press].
57. Soriano V, Maida I, Garcia-Samaniego J, Nuñez M, Barreiro P, Gonzalez-Lahoz J. Long-term follow-up of HIV-infected patients with chronic HCV infection treated with IFN-based therapies. Antivir Ther 2004;9:987-92.
58. Desmond C, Roberts S, Dudley F, et al. Sustained virologic response rates and durability of the response to IFN-based therapies in hepatitis C patients treated in the clinical setting. J Viral Hepat 2006;13:290-6.
59. Sylvestre D. Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug Alcohol Depend 2002;67:117-23.
60. Backmund M, Meyer K, von Zielonka V, Eichenlaub D. Treatment of hepatitis C infection in injection drug users. Hepatology 2001;34:186-93.
61. Edlin B. Prevention and treatment of hepatitis C in injecting drug users. Hepatology 2002;36(Suppl):210-9.
62. NIH Consensus Development Conference Statement: management of hepatitis C. Gastroenterology 2002;123:2082-99.
63. Malda I, Soriano V, Barreiro P, Rivas P, Labarga P, Nuñez M. Liver fibrosis stage and HCV genotype distribution in HIV/HCV-coinfected patients with persistently normal transaminases. AIDS Res Human Retroviruses 2007 [in press].
64. Uberti-Foppa C, De Bona A, Galli L, et al. Liver fibrosis in HIV-positive patients with HCV: role of persistently normal ALT levels. J Acquir Immune Defic Syndr 2006;41:63-7.
65. Mathurin P, Moussalli J, Cadranel J, et al. Slow progression rate of fibrosis in HCV patients with persistently normal ALT activity. Hepatology 1998;27:868-72.
66. Okanoue T, Makiyama A, Nakayama M, et al. A follow-up study to determine the value of liver biopsy and need for antiviral therapy for HCV carriers with persistently normal serum aminotransferases. J Hepatol 2005;43:599-605.
67. Sterling R, Contos M, Sanyal A, et al. The clinical spectrum of HCV in HIV coinfection. J Acquir Immune Defic Syndr 2003;32:30-7.
68. Bani-Dadr F, Carrat F, Goderel I, et al. Risk factors for bacterial infections in HCV/HIV-coinfected patients during IFN plus ribavirin-based therapy. J Hepatol 2006;44(Suppl 2):207.
69. Romero-Gomez M, Del M, V, Andrade R, et al. Insulin resistance impairs sustained response rate to PEG-IFN plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005;128:636-41.
70. Dube M. Disorders of glucose metabolism in patients infected with HIV. Clin Infect Dis 2000;31:1467-75.
71. Garcia-Benayas T, Rendon A, Rodriguez-Novoa S, et al. Higher risk of hyperglycemia in HIV-infected patients treated with didanosine plus tenofovir. AIDS Res Hum Retroviruses 2006;22:333-7.
72. Ratziu V, Charlotte F, Jacqueminet S, et al. A one year randomized, placebo-controlled, double-blind trial of rosiglitazone in NASH; results of the FLIRT pilot trial. J Hepatol 2006;44(Suppl 2):272.
73. McHutchison J, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-l-infected patients with chronic hepatitis C. Gastroenterology 2002;123:1061-9.
74. Soriano V. Treatment of chronic hepatitis C in HIV-positive individuals: selection of candidates. J Hepatol 2006;44(Suppl 1):44-8.
75. Laguno M, Blanch J, Murillas J, et al. Depressive symptoms after initiation of IFN therapy in HIV-infected patients with chronic hepatitis C. Antivir Ther 2004;9:905-9.
76. Afdhal N, Dieterich D, Pockros P, et al. Epoetin-α maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology 2004;126:1302-11.
77. Sulkowski M, Dieterich D, Bini E, et al. Epoetin-α once weekly improves anemia in HIV/HCV-coinfected patients treated with IFN/ribavirin: a randomized controlled trial. J Acquir Immune Defic Syndr 2005;39:504-6.
78. Ramos B, Nuñez M, Rendon A, et al. Critical role of ribavirin for the achievement of early virologic response to HCV therapy in HCV/HIV-coinfected patients. J Viral Hepat 2007 [in press].
79. Soriano V, Nuñez M, Camino N, Barreiro P, Garcia-Samaniego J, Gonzalez-Lahoz J. HCV-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with PEG-IFN plus ribavirin. Antivir Ther 2004;9:505-9.
80. Torriani F, Ribeiro R, Gilbert T, et al. HCV and HIV dynamics during HCV treatment in HCV/HIV coinfection. J Infect Dis 2003;188: 1498-507.
81. McHutchison J, Shiffman M, Gordon S, et al. Sustained virologic response to IFNα-2b ± ribavirin therapy at 6 months reliably predicts long-term clearance of HCV at 5 year follow-up. J Hepatol 2006; 44(Suppl 2):275.
82. Jacobson I, Brown R, Frielich B. Weight-based ribavirin dosing increases sustained virologic response in patients with chronic hepatitis C: final results of the WIN-R trial, a US community based trial. 56th Annual Meeting of the American Association for the Study of the Liver Disease; November 11-15, 2005. San Francisco, CA [abstract LB03].
83. Lindahl K, Stahle L, Bruchfeld A, Schvarcz R. High-dose ribavirin in combination with standard dose PEG-IFN for treatment of patients with chronic hepatitis C. Hepatology 2005;41:275-9.
84. Nuñez M, Camino N, Ramos B, et al. Impact of ribavirin exposure on early virologic response to hepatitis C therapy in HIV-infected patients with chronic hepatitis C. Antivir Ther 2005;10:657-62.
85. Jen J, Glue P, Gupta S, Zambas D, Hajian G. Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C. Ther Drug Monit 2000;22:555-65.
86. Rendon A, Nunez M, Romero M, et al. Early monitoring of ribavirin plasma concentrations may predict anemia and early virologic response in HIV/ HCV-coinfected patients. J Acquir Immune Defic Syndr 2005;39:401-5.
87. Soriano V, Nuñez M, Miralles C, et al. The PRESCO trial: Role of extended duration of therapy with PEG-IFN plus weight-based ribavirin doses in 389 HIV/HCV coinfected-patients. 8th International Congress on Drug Therapy in HIV Infection. November 12-15, 2006. Glasgow, UK [abstract LB-2].
88. Perelson A, Ribeiro R. Mutagenic effects of ribavirin in vivo. J Hepatol 2005;43:553-5.
89. Dixit N, Layden-Almer J, Layden T, Perelson A. Modeling how ribavirin improves IFN response rates in HCV infection. Nature 2004;432:922-4.
90. Hadziyannis S, Sette H, Morgan T, et al. PEG-IFNα-2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140: 346-55.
91. Mangia A, Santoro R, Minerva N, et al. PEG-IFNα-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005; 352:2609-17.
92. Shiffman M, Pappas S, Nyberg L, et al. PEG-IFNα-2a plus ribavirin for 16 or 24 weeks in patients with HCV genotypes 2 or 3. Final results of the ACCELERATE trial. J Hepatol 2006;44(Suppl 2):271.
93. Brau N, Rodriguez-Torres M, Prokupek D, et al. Treatment of chronic hepatitis C in HIV/HCV-coinfection with IFNα-2b+ribavirin full-course vs. 16-week delayed ribavirin. Hepatology 2004;39:989-98.
94. Sola R, Tural C, Rubio R, et al. Lack of benefit of an induction dose of PEG-IFNα-2a on early HCV kinetics in HIV/HCV-coinfected patients: results from the CORAL-1 pilot, multicenter study. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy; December 16-19, 2005. Washington, DC [abstract 416b].
95. Marcellin P, Teuber G, Canva V, et al. Efficacy of standard dose and fixed dose induction PEG-IFNα-2a plus ribavirin among PEG-IFNα-2b/ribavirin nonresponders: interim analysis of the REPEAT study. J Hepatol 2006;44(Suppl 2):7.
96. Ferenci P, Bergholz U, Laferl H, et al. 24 week treatment regimen with PEG-IFNα-2a plus ribavirin in HCV genotype 1 or 4 "superresponders". J Hepatol 2006;44(Suppl 2):6.
97. Zeuzem S, Buti M, Ferenci P, et al. Efficacy of 24 weeks treatment with PEG-IFNα-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pre-treatment viremia. J Hepatol 2006;44:97-103.
98. Crespo M, Esteban J, Ribera E, et al. Utility of week 4 viral response to tailor treatment duration in HCV genotype 3/HIV-coinfected patients. AIDS 2007;21:477-81.
99. Hopkins S, Lambourne J, Farrell G, et al. Role of individualization of HCV therapy duration in HIV/HCV-coinfected individuals. HIV Med 2006;7:248-54.
100. Dieterich D, Duff F, Sulkowski M, et al. Sustained virologic response in HIV/HCV coinfected patients with HCV genotype 1 infection who have a rapid virologic response at week 4 of treatment with PEG-IFNα-2a plus ribavirin: APRICOT trial. 13th CROI; February 5-8, 2006. Denver, CO [abstract 856].
101. Zanini B, Puoti M, Quiros E, et al. The optimal duration of treatment for HIV-infected patients with chronic hepatitis C and genotypes 2 or 3 is 48 weeks: results of a randomized controlled trial. 3rd IAS Conference on HIV Pathogenesis and Treatment. Rio de Janeiro, 24-27 July 2005 [abstract 678].
102. Nuñez M, Mariño A, Miralles C, et al. Baseline HCV-RNA and response at week 4 are the best predictors of relapse following treatment with PEG-IFN plus ribavirin in HIV/HCV-coinfected patients. J Acquir Immune Defic Syndr 2007 [in press].
103. Buti M, Valdes A, Sanchez-Avila F, Esteban R, Lurie Y. Extending combination therapy with PEG-IFNα-2b plus ribavirin for genotype 1 chronic hepatitis C late responders: a report of 9 cases. Hepatology 2003;37:1226-7.
104. Berg T, von Wagner M, Nasser S, et al. Extended treatment duration for HCV type 1: comparing 48 vs. 72 weeks of PEG-IFNα-2a plus ribavirin. Gastroenterology 2006;130:1086-97.
105. Sanchez-Tapias JM, Diago M, Escartin P, et al. PEG-IFNα-2a plus ribavirin for 72 weeks in chronic hepatitis C patients without a response by week 4. Gastroenterology 2006;131:451-60.
106. Fontana R. Optimizing outcomes in hepatitis C: is treatment beyond 48 weeks ever justified? Gastroenterology 2006;130: 1357-62.
107. Fuster D, Planas R, Gonzalez J, et al. Results of a study of prolonging treatment with PEG-IFNα-2a plus ribavirin in HIV/HCV-coinfected patients with no early virologic response. Antivir Ther 2006; 11:473-82.
108. Soriano V, Puoti M, Sulkowski M, et al. Care of patients coinfected with HIV and HCV: 2007 Updated recommendations from the HCV-HIV International Panel. AIDS 2007;21:1073-89.
109. Uriel A, Moorehead L, Carriero D, Sulkowski M, Dieterich D, and the Hepatitis Resource Network Clinical Trials Group. A multicenter, randomized trial of 48 vs. 72 weeks of PEG-IFNα-2b + ribavirin in HIV/HCV-coinfected subjects: longer therapy does not correlate with improved sustained virologic response. 13th CROI; February 5-8, 2006. Denver, CO [abstract 854].
110. Mauss S, Valenti W, Depamphilis J, et al. Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during IFN-based therapy. AIDS 2004;18:F21-5.
111. Bani-Sadr F, Carrat F, Pol S, et al. Risk factors for symptomatic mitochondrial toxicity in HIV/HCV-coinfected patients during IFN plus ribavirin-based therapy. J Acquir Immune Defic Syndr 2005;40:47-52.
112. Garcia-Benayas T, Blanco F, Soriano V. Weight loss in HIV-infected patients. N Engl J Med 2002;347:1287-8.
113. Bani-Sadr F, Denoeud L, Morand P, et al. Early virologic failure in HIV-coinfected hepatitis C patients treated with PEG-IFN/RBV combination. J Acquir Immune Defic Syndr 2007;45:123-5.
114. Vispo E, Barreiro P, Maida I, et al. Abacavir-containing HAART reduces the chances for SVR to PEG-IFN plus ribavirin in HIV-infected patients with chronic hepatitis C. 3rd International Workshop on HIV and Hepatitis Coinfection. Paris, France. June 7-9 2007 [abstract 45].
115. Graci J, Cameron C. Quasispecies, error catastrophe, and the antiviral activity of ribavirin. Virology 2002;298:175-80.
116. Parker W. Metabolism and antiviral activity of ribavirin. Virus Res 2005;107:165-71.
117. Hofmann W, Polta A, Hermann E, et al. Mutagenic effect of ribavirin on hepatitis C nonstructural 5B quasispecies in vitro and during antiviral therapy. Gastroenterology 2007;132:921-30.
118. Lutchman G, Danehower S, Song B, et al. Mutation rate of the HCV NS5B in patients undergoing treatment with ribavirin monotherapy. Gastroenterology 2007;132:1757-66.
119. Perelson A, Layden T. Ribavirin: is it a mutagen for HCV? Gastroenterology 2007;132:2050-2.
120. Chevaliez S, Brillet R, Lazaro E, Hezode C, Pawlotsky J. Analysis of ribavirin mutagenicity in HCV infection. J Virol 2007 [in press].
121. Lanford R, Chavez D, Guerra B, et al. Ribavirin induces error-prone replication of GB virus B in primary tamarin hepatocytes. J Virol 2001;75:8074-81.
122. Vignuzzi M, Stone J, Andino R. Ribavirin and lethal mutagenesis of poliovirus: molecular mechanisms, resistance and biological implications. Virus Res 2005;107:173-81.
123. Sun Y, Chung D-H, Chu Y-K, Jonsson C, Parker W. Activity of ribavirin against Hantaan virus correlates with production of ribavirin-5′-triphosphate, not with inhibition of IMP dehydrogenase. Antimicrob Agents Chemother 2007;51:84-8.
124. Sierra M, Airaksinen A, Gonzalez-Lopez C, Agudo R, Arias A, Domingo E. Foot-and-mouth disease virus mutant with decreased sensitivity to ribavirin: implications for error catastrophe. J Virol 2007;81:2012-24.
125. Sanchez-Conde M, Gil P, Sanchez-Somolinos M, Gonzalez-Lahoz J, Soriano V. Hepatic and renal safety profile of tenofovir in HIV-infected patients with hepatitis C, including patients on IFN plus ribavirin. HIV Clin Trials 2005;6:278-80.